# CHERISH (CS4) Nusinersen vs Sham Control in Later-Onset SMA

Keywords: SMA, 5q SMA, nusinersen, CHERISH trial, adverse events, motor function, safety, clinical trial

> This page provides detailed information about the CHERISH (CS4) clinical trial, which evaluated the efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA), including data on adverse events, motor function improvements, and study design.

## Details

- [Adverse Events](#): Summary of adverse events observed during the CHERISH trial, showing comparable overall incidence between the nusinersen and control groups, with no treatment discontinuations.
- [Study Description](#): Overview of the CHERISH trial, a Phase III randomized study assessing nusinersen's impact on motor function and safety in children with later-onset SMA.
- [Further Study Information](#): Insights into the trial's outcomes, highlighting significant motor function improvements in the nusinersen group compared to the control group.
- [References](#): List of sources and publications supporting the trial's findings and methodology.